Emerging Pharmacotherapies to Fight Obesity and Related Disorders
作者： T Handjieva-Darlenska , N Boyadjieva , K Takov
DOI: 10.4172/2165-7904.1000226
关键词:
摘要: Obesity is a chronic disease, characterized by an accumulation of excess adipose tissue and associated with increased risk for cardio-vascular diseases mortality. Weight loss 5-10% prevents or tempers the severity many obesity-related morbidities. The current therapy obesity comprises diet, physical activity, pharmacotherapy. At moment, only approved drug treatment in European Union Orlistat. This paper covers latest research field emphasis on modulation different physiological systems peptides regulation appetite metabolism through drugs as well new to treat diabetes type 2 obesity. Furthermore, authors show own data results animal models humans.
omicsonline.org
cabdirect.org参考文章(37)
Christopher H. Fazen, Debbie Valentin, Timothy J. Fairchild, Robert P. Doyle, Oral delivery of the appetite suppressing peptide hPYY(3-36) through the vitamin B12 uptake pathway. Journal of Medicinal Chemistry. ,vol. 54, pp. 8707- 8711 ,(2011) , 10.1021/JM2012547
Benjamin C. T. Field, James S. Minnion, Joyceline Cuenco-Shillito, Edward S. Chambers, Sagen Zac-Varghese, Charlie J. Brindley, Shahrul Mt-Isa, Francesca Fiorentino, Deborah Ashby, Ian Ward, Mohammad A. Ghatei, Stephen R. Bloom, Tricia M. Tan, Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420 British Journal of Clinical Pharmacology. ,vol. 73, pp. 232- 239 ,(2012) , 10.1111/J.1365-2125.2011.04082.X
Reuben J Shaw, Metformin trims fats to restore insulin sensitivity. Nature Medicine. ,vol. 19, pp. 1570- 1572 ,(2013) , 10.1038/NM.3414
G. B. Bolli, D. R. Owens, Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus Diabetes, Obesity and Metabolism. ,vol. 16, pp. 588- 601 ,(2014) , 10.1111/DOM.12253
Tricia Tan, Stephen Bloom, Gut hormones as therapeutic agents in treatment of diabetes and obesity. Current Opinion in Pharmacology. ,vol. 13, pp. 996- 1001 ,(2013) , 10.1016/J.COPH.2013.09.005
Nigel Irwin, Peter R Flatt, Enteroendocrine hormone mimetics for the treatment of obesity and diabetes. Current Opinion in Pharmacology. ,vol. 13, pp. 989- 995 ,(2013) , 10.1016/J.COPH.2013.09.009
T A Wadden, , P Hollander, S Klein, K Niswender, V Woo, P M Hale, L Aronne, Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study International Journal of Obesity. ,vol. 37, pp. 1443- 1451 ,(2013) , 10.1038/IJO.2013.120
Gisela Robles, A review of exenatide as adjunctive therapy in patients with type 2 diabetes Drug Design Development and Therapy. ,vol. 3, pp. 219- 240 ,(2009) , 10.2147/DDDT.S3321
Kiyohiko Nakai, Russell Wada, Satofumi Iida, Takehiko Kawanishi, Yoshiaki Matsumoto, Modeling and Simulation of Orlistat to Predict Weight Loss and Weight Maintenance in Obesity Patients Drug Metabolism and Pharmacokinetics. ,vol. 29, pp. 278- 282 ,(2014) , 10.2133/DMPK.DMPK-13-RG-100
Andres Acosta, Maria D. Hurtado, Oleg Gorbatyuk, Michael La Sala, David Duncan, George Aslanidi, Martha Campbell-Thompson, Lei Zhang, Herbert Herzog, Antonis Voutetakis, Bruce J. Baum, Sergei Zolotukhin, Salivary PYY: A Putative Bypass to Satiety PLoS ONE. ,vol. 6, pp. e26137- ,(2011) , 10.1371/JOURNAL.PONE.0026137